Eagle Pharmaceuticals Receivables 2013-2023 | EGRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Eagle Pharmaceuticals receivables from 2013 to 2023. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Eagle Pharmaceuticals receivables from 2013 to 2023. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$194.8B
Boston Scientific (BSX)	$139.8B
Stryker (SYK)	$139.4B
EssilorLuxottica (ESLOY)	$110.1B
Medtronic (MDT)	$103.4B
Lonza Group Ag (LZAGY)	$43.7B
Haleon (HLN)	$41.2B
GE HealthCare Technologies (GEHC)	$38.7B
ResMed (RMD)	$34.3B
Terumo (TRUMY)	$28B
Koninklijke Philips (PHG)	$24.3B
Zimmer Biomet Holdings (ZBH)	$20.8B
Insulet (PODD)	$19.1B
Baxter (BAX)	$15B
Smith & Nephew SNATS (SNN)	$10.5B
Bio-Rad Laboratories (BIO)	$9.6B
BellRing Brands (BRBR)	$9.1B
Demant (WILYY)	$8.6B
Lantheus Holdings (LNTH)	$6.7B
Haemonetics (HAE)	$3.9B
ICU Medical (ICUI)	$3.8B
Prestige Consumer Healthcare (PBH)	$3.7B
Perrigo (PRGO)	$3.3B
Envista Holdings (NVST)	$3.2B
QuidelOrtho (QDEL)	$3.1B
Shandong Weigao Medical Polymer (SHWGF)	$3B
Neogen (NEOG)	$2.7B
GN Store Nord (GNNDY)	$2.6B
LeMaitre Vascular (LMAT)	$2.1B
Green Thumb Industries (GTBIF)	$1.6B